Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E S Dietrich

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Deutsche Medizinische Wochenschrift (1946)|February 19, 2010
[Pharmacoeconomic studies - usability for reimbursement decisions]E S Dietrich, T Nakashima, S Ahrens
Pharmacoeconomics|March 17, 2001
Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infectionE S Dietrich, B Schubert, W Ebner, et al.
Infection|February 23, 1999
Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in GermanyE S Dietrich, E Patz, U Frank, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 9, 2010
Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in GermanyS Pscherer, E S Dietrich, F-W Dippel, et al.
Infection|May 23, 2002
Nosocomial pneumonia: a cost-of-illness analysisE S Dietrich, M Demmler, G Schulgen, et al.
Infection|April 29, 1999
Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in GermanyE S Dietrich, U Joseph, F Vogel, et al.
Pneumologie (Stuttgart, Germany)|December 15, 2004
[Cost-of-illness Study for the Treatment of COPD in Germany]D Nowak, E S Dietrich, P Oberender, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Deutsche Medizinische Wochenschrift (1946)|February 19, 2010
[Pharmacoeconomic studies - usability for reimbursement decisions]E S Dietrich, T Nakashima, S Ahrens
Pharmacoeconomics|March 17, 2001
Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infectionE S Dietrich, B Schubert, W Ebner, et al.
Infection|February 23, 1999
Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in GermanyE S Dietrich, E Patz, U Frank, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 9, 2010
Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in GermanyS Pscherer, E S Dietrich, F-W Dippel, et al.
Infection|May 23, 2002
Nosocomial pneumonia: a cost-of-illness analysisE S Dietrich, M Demmler, G Schulgen, et al.
Infection|April 29, 1999
Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in GermanyE S Dietrich, U Joseph, F Vogel, et al.
Pneumologie (Stuttgart, Germany)|December 15, 2004
[Cost-of-illness Study for the Treatment of COPD in Germany]D Nowak, E S Dietrich, P Oberender, et al.
Pageof 1